Nov 5, A trial of Pfizer Inc’s (PFE.N) experimental antiviral pill for COVID-19 was conducted and showed more than 89% results. “Implications of effective therapeutics for ending the pandemic are very, very large,” said Ashish Jha, dean of the Brown University School of Public Health. After the announcement, shares of Pfizer have surged 11% to $48.55, while those of Merck fell 8.5% to $82.80.
